Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker.

Anhye Kim, Jungryul Kim, Dongseong Shin, Yang Won Min, In Hee Kim, Youlim Seo, Deborah Kang

Journal: Advances in therapy 2025;42(3):1570-1581

PMID: 39932678

Abstract

INTRODUCTION

Tegoprazan is a potassium-competitive acid blocker, and its systemic exposure is presumably affected by hepatic clearance and bioavailability. This study aimed to investigate the effect of hepatic impairment (HI) on the safety and pharmacokinetics of tegoprazan and metabolite.

METHODS

An open-label, multicenter, parallel-group study was conducted in patients with mild (n = 8), moderate (n = 8) and severe (n = 1) HI according to the Child-Pugh classification as well as controls. Healthy subjects (n = 8) were matched to patients with the moderate category based on age, body mass index and sex. Blood and urine samples were obtained to evaluate the concentrations of tegoprazan and metabolite (M1) until 48 h after a single oral administration of 50 mg of tegoprazan.

RESULTS

The geometric mean ratio with a 90% confidence interval of maximum plasma concentration and area under the plasma concentration-time curve for tegoprazan in patients with impaired hepatic function compared to controls were 0.8228 (0.4997-1.3550) and 1.2264 (0.7447-2.0197) in the mild category, 1.0332 (0.6274-1.7015) and 1.7676 (1.0733-2.9109) in the moderate category, and 1.0699 (0.3713-3.0823) and 1.9567 (0.6792-5.6377) in the severe category. The half-life, apparent clearance, renal clearance, and fraction unbound to plasma protein were comparable across study groups. The plasma concentration of M1 increased and decreased faster in the normal group. Tegoprazan was generally well tolerated in patients with HI.

CONCLUSIONS

Systemic exposure to tegoprazan tended to be increased in subjects with HI. The difference between patients with mild HI and the controls was deemed not to require dose adjustment for tegoprazan.

CLINICAL TRIAL REGISTRATION

ClinicalTrials.gov identifiers: NCT04494269 (31 Jul 2020).

© 2025. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.

Address: Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, CHA University, Seongnam, Republic of Korea.; Department of Pharmacology, CHA University School of Medicine, Pocheon, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Gachon University College of Medicine, Gil Medical Center, Incheon, Republic of Korea.; Clinical Research Center, HK inno.N Corp, Seoul, Republic of Korea.; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.